Diffuse palmoplantar keratoderma
MONDO:0017666Palmoplantar keratoderma that diffusely involves most of the palm and sole and is caused by a genetic abnormality.
Also known as: diffuse PPK, diffuse keratosis palmoplantaris, diffuse palmoplantar hyperkeratosis
12 clinical trials for this condition and its sub-types, 0 tagged with Diffuse palmoplantar keratoderma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Diffuse palmoplantar keratoderma
-
Papillon-Lefevre disease 5 trials
-
Odonto-onycho-dermal dysplasia 2 trials
-
Bart-Pumphrey syndrome 0 trials
-
CEDNIK syndrome 0 trials
-
Clouston syndrome 0 trials
-
Haim-Munk syndrome 0 trials
-
KID syndrome 0 trials
-
Schöpf-Schulz-Passarge syndrome 0 trials
-
Dermatopathia pigmentosa reticularis 0 trials
-
Erythrokeratodermia variabilis 0 trials
8 sub-types
- Erythrokeratodermia variabilis et progressiva 1 0 trials
- Erythrokeratodermia variabilis et progressiva 2 0 trials
- Erythrokeratodermia variabilis et progressiva 3 0 trials
- Erythrokeratodermia variabilis et progressiva 4 0 trials
- Erythrokeratodermia variabilis et progressiva 5 0 trials
- Erythrokeratodermia variabilis et progressiva 6 0 trials
- Erythrokeratodermia variabilis et progressiva 7 0 trials
- Transgrediens et progrediens palmoplantar keratoderma 0 trials
-
Hearing loss with skin disease 0 trials
-
Loricrin keratoderma 0 trials
-
Mal de Meleda 0 trials
-
1 sub-type
-
Could a cancer pill ease rare, painful skin diseases?
Disease control Not yet recruitingThis early-phase trial tests whether low doses of erlotinib, a drug originally used for cancer, can improve symptoms of rare genetic skin conditions called keratinopathies. About 44 adults with confirmed diagnoses will take increasing doses over 24 weeks. The goal is to see if it…
Phase 1/2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Could a supplement boost prostate cancer treatment?
Disease control Not yet recruitingThis early-phase trial tests whether adding a dietary supplement called LC-K76 to standard hormone therapy is safe for men with metastatic hormone-sensitive prostate cancer. Forty men will receive the supplement plus hormone therapy for 24 weeks, then be followed for another 24 w…
Early phase 1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New test may predict prostate cancer treatment success
Knowledge-focused Not yet recruitingThis study looks at whether a test called minimal residual disease (MRD) can help predict how well treatment works in men with metastatic hormone-sensitive prostate cancer. Researchers will track 50 newly diagnosed patients to see how different gene patterns affect treatment resp…
Sponsor: Anhui Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC